Law firm WeissLaw said it is investigating “possible breaches of fiduciary duty and other violations of law” by the board of directors of Big Rock Partners Acquisition in connection with the company’s proposed $500 million merger with privately-held clinical stage, small molecule pharmaceutical company NeuroRx. Read more.
Related Posts
RMG Acquisition III Shares & Warrants Begin Separate Trading
The SPAC will concentrate on companies in any sector with enterprise values between $1 billion and $4 billion.
Silver Spike III Winding Up
Silver Spike II shut down in March after failing to complete a deal.
Haymaker II Files Definitive Proxy on Arko Merger
Additional disclosures include a shareholder lawsuit pending against the SPAC, alleging breach of fiduciary duty, which Haymaker said is without merit.
Financial Strategies Acquisition Stock, Rights & Warrants to Begin Separate Trading
The new SPAC is targeting fintech companies with an equity value of approximately $300 million to $500 million.